Description

Simple

A medication used to treat and relieve painful conditions in the uterus and breasts.

Clinical

A synthetic steroid and pituitary gonadotropin inhibitor used in the treatment of endometriosis and symptomatic treatment of severe pain and tenderness associated with benign fibrocystic breasts.

Overview

A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.

Pharmacology

Indication

For the treatment of endometriosis and fibrocystic breast disease (in patients unresponsive to simple measures). Also used for the prophylactic treatment of all types of hereditary angioedema in males and females.

Pharmacodynamic

Danazol is a derivative of the synthetic steroid ethisterone, a modified testosterone. It was approved by the U.S. Food and Drug Administration (FDA) as the first drug to specifically treat endometriosis, but its role as a treatment for endometriosis has been largely replaced by the gonadotropin-rel... Read more

Mechanism of action

As a gonadotropin inhibitor, danazol suppresses the pituitary-ovarian axis possibly by inhibiting the output of pituitary gonadotropins. Danazol also depresses the preovulatory surge in output of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), thereby reducing ovarian estrogen produ... Read more

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Approximately 24 hours.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

  • Regions: US
  • Patient Conditions:
      • Name: Potential for pregnancy
      • Drugbank Id: DBCOND0108358
  • Regions: US
  • Patient Conditions:
      • Name: Pregnancy
      • Drugbank Id: DBCOND0018394
  • Regions: US
  • Patient Conditions:
      • Name: Breastfeeding
      • Drugbank Id: DBCOND0031330
  • Regions: US
  • Patient Conditions:
      • Name: Undiagnosed abnormal genital bleeding
      • Drugbank Id: DBCOND0107557
  • Regions: US
  • Patient Conditions:
      • Name: Androgen-dependent tumor
      • Drugbank Id: DBCOND0108360
  • Regions: US
  • Patient Conditions:
      • Name: Active thrombosis
      • Drugbank Id: DBCOND0108361
      • Modification Of:
        • Condition Status: active
        • Base:
          • Name: Thrombosis
          • Drugbank Id: DBCOND0020122
  • Regions: US
  • Patient Conditions:
      • Name: Markedly impaired hepatic, renal, or cardiac function
      • Drugbank Id: DBCOND0108359
  • Regions: US
  • Patient Conditions:
      • Name: Porphyria
      • Drugbank Id: DBCOND0008396
  • Regions: US
  • Patient Conditions:
      • Name: Thromboembolic disease and history of such events
      • Drugbank Id: DBCOND0108362

Food Interactions

  • Take with or without food. The absorption is unaffected by food.

Interactions

Type in a drug name to check for interaction with Danazol
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(R)-warfarin
The serum concentration of (R)-warfarin can be increased when it is combined with Danazol.
(S)-Warfarin
The serum concentration of (S)-Warfarin can be increased when it is combined with Danazol.
1alpha-Hydroxyvitamin D5
Danazol may increase the hypercalcemic activities of 1alpha-Hydroxyvitamin D5.
1alpha,24S-Dihydroxyvitamin D2
Danazol may increase the hypercalcemic activities of 1alpha,24S-Dihydroxyvitamin D2.
2,4-thiazolidinedione
The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Danazol.
4-hydroxycoumarin
The metabolism of 4-hydroxycoumarin can be decreased when combined with Danazol.
9-aminocamptothecin
The metabolism of 9-aminocamptothecin can be decreased when combined with Danazol.
Acarbose
The therapeutic efficacy of Acarbose can be decreased when used in combination with Danazol.
Acenocoumarol
The serum concentration of Acenocoumarol can be increased when it is combined with Danazol.
Acetohexamide
The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Danazol.
AICA ribonucleotide
The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Danazol.
Albendazole
The metabolism of Albendazole can be decreased when combined with Danazol.
Albiglutide
The therapeutic efficacy of Albiglutide can be decreased when used in combination with Danazol.
Aldosterone
The risk or severity of fluid retention can be increased when Aldosterone is combined with Danazol.
Alfacalcidol
Danazol may increase the hypercalcemic activities of Alfacalcidol.
Alfentanil
The metabolism of Alfentanil can be decreased when combined with Danazol.
Alfuzosin
The metabolism of Alfuzosin can be decreased when combined with Danazol.
Allicin
The therapeutic efficacy of Allicin can be decreased when used in combination with Danazol.
Allylestrenol
The metabolism of Allylestrenol can be decreased when combined with Danazol.
Alogliptin
The therapeutic efficacy of Alogliptin can be decreased when used in combination with Danazol.
3 References
  1. 1 . Dmowski WP: Danazol. A synthetic steroid with diverse biologic effects. J Reprod Med. 1990 Jan;35(1 Suppl):69-74; discussion 74-5.PubMed: 2404115
  2. 2 . Donaldson VH: Danazol. Am J Med. 1989 Sep;87(3N):49N-55N.PubMed: 2486535
  3. 3 . Jenkin G: Review: The mechanism of action of danazol, a novel steroid derivative. Aust N Z J Obstet Gynaecol. 1980 May;20(2):113-8.PubMed: 6998453